摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N,N-Diethyl-2-(trifluoromethyl)benzamide | 57547-96-3

中文名称
——
中文别名
——
英文名称
N,N-Diethyl-2-(trifluoromethyl)benzamide
英文别名
——
N,N-Diethyl-2-(trifluoromethyl)benzamide化学式
CAS
57547-96-3
化学式
C12H14F3NO
mdl
MFCD20143038
分子量
245.244
InChiKey
UKTAHUUHLAKXHN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    313.2±42.0 °C(Predicted)
  • 密度:
    1.160±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    17
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.416
  • 拓扑面积:
    20.3
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    N,N-Diethyl-2-(trifluoromethyl)benzamide 在 palladium on activated charcoal 盐酸四甲基乙二胺氢气仲丁基锂sodium acetate溶剂黄146 作用下, 以 四氢呋喃乙醇正己烷二氯甲烷 为溶剂, -78.0~100.0 ℃ 、551.58 kPa 条件下, 反应 113.5h, 生成 N-(tert-butoxycarbonyl)-(R)-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one
    参考文献:
    名称:
    Discovery of (R)-9-Ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a Selective, Orally Active Agonist of the 5-HT2C Receptor
    摘要:
    Robust pharmaceutical treatment of obesity has been limited by the undesirable side-effect profile of currently marketed therapies. This paper describes the synthesis and optimization of a new class of pyrazinoisoindolone-containing, selective 5-HT2C agonists as antiobesity agents. Key to optimization of the pyrazinoisoindolone core was the identification of the appropriate substitution pattern and functional groups which led to the discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one (58), a 5-HT2C agonist with > 300-fold functional selectivity over 5-HT2B and > 70-fold functional selectivity over 5-HT2A. Oral dosing of 58 reduced food intake in an acute rat feeding model, which could be completely reversed by a selective 5-HT2C antagonist and caused a reduction in body weight gain in a 4-day rat model.
    DOI:
    10.1021/jm0612968
  • 作为产物:
    描述:
    参考文献:
    名称:
    一类具有驱蚊作用的含氟苯甲酰二乙胺类化合物、方法及在驱蚊剂中的应用
    摘要:
    本发明属于化合物技术领域,公开了一类具有驱蚊作用的含氟苯甲酰二乙胺类化合物,所述含氟苯甲酰二乙胺类化合物的结构通式如下:#imgabs0#式Ⅰ中,R1‑R5各自独立的或共同的选自氢、氟、甲基、三氟甲基中的任意一种,且R1‑R5至少有一个基团含有氟元素。本发明含氟苯甲酰二乙胺类化合物对蚊子具有明显的驱避效果,在质量浓度为1%,施涂剂量0.04mg/cm2条件下,活性最高的化合物驱避蚊子的有效保护时间为162min,相比避蚊胺(DEET)高出一倍。
    公开号:
    CN117486753A
点击查看最新优质反应信息

文献信息

  • Fungicides for the control of take-all disease of plants
    申请人:Monsanto Company
    公开号:US05498630A1
    公开(公告)日:1996-03-12
    A method of controlling Take-All disease of plants by applying a fungicide of the formula ##STR1## wherein Z1 and Z2 are C and are part of an aromatic ring which is benzothiophene; and A is selected from --C(X)-amine wherein the amine is an unsubstituted, monosubstituted or disubstituted amino radical, --C(O)--SR.sub.3, --NH--C(X)R.sub.4, and --C(.dbd.NR.sub.3)--XR.sub.7 ; B is --W.sub.m --Q(R.sub.2).sub.3 or selected from O-tolyl, 1-naphthyl, 2-naphthyl, and 9-phenanthryl, each optionally substituted with halogen or R.sub.4 ; Q is C, Si, Ge, or Sn; W is --C(R.sub.3).sub.p H.sub.(2-p) --; or when Q is C, W is selected from --C(R.sub.3).sub.p H(.sub.2-p), --N(R.sub.3).sub.m H(.sub.1-m)--, --S(O)p--, and --O--; X is 0 or S; n is 0, 1, 2, or 3; m is 0 or 1; p is 0, 1, or 2; each R and R.sub.2 is independently defined herein; R.sub.3 is C.sub.1 -C.sub.4 alkyl; R.sub.4 is C.sub.1 -C.sub.4 alkyl, haloalkyl, alkoxy, alkylthio, alkylamino, or dialkylamino; and R.sub.7 is C.sub.1 -C.sub.4 alkyl, haloalkyl, or phenyl, optionally substituted with halo, nitro, or R.sub.4 ; or an agronomic salt thereof.
    一种通过施用公式##STR1##的杀菌剂来控制植物全蚀病的方法,其中Z1和Z2为C,并且是苯并噻吩的芳香环的一部分;A从--C(X)-胺中选择,其中胺是未取代的、单取代的或双取代的基基团,--C(O)--SR.sub.3,--NH--C(X)R.sub.4和--C(.dbd.NR.sub.3)--XR.sub.7;B为--W.sub.m --Q(R.sub.2).sub.3或从O-甲苯基、1-基、2-基和9-基中选择,每个都可以选择性地用卤素或R.sub.4取代;Q为C、Si、Ge或Sn;W为--C(R.sub.3).sub.p H.sub.(2-p)--;或当Q为C时,W从--C(R.sub.3).sub.p H(.sub.2-p),--N(R.sub.3).sub.m H(.sub.1-m)--,--S(O)p--和--O--中选择;X为0或S;n为0、1、2或3;m为0或1;p为0、1或2;每个R和R.sub.2在此独立定义;R.sub.3为C.sub.1 -C.sub.4烷基;R.sub.4为C.sub.1 -C.sub.4烷基、卤代烷基、烷基、烷基、烷基基或二烷基基;R.sub.7为C.sub.1 -C.sub.4烷基、卤代烷基或基,可以选择性地用卤素、硝基或R.sub.4取代;或其农艺学盐。
  • meta-Selective C–H Borylation of Benzamides and Pyridines by an Iridium–Lewis Acid Bifunctional Catalyst
    作者:Lichen Yang、Nao Uemura、Yoshiaki Nakao
    DOI:10.1021/jacs.9b03138
    日期:2019.5.15
    We report herein the iridium-catalyzed meta-selective C-H borylation of benzamides by using a newly designed 2,2'-bipyridine (bpy) ligand bearing an alkylaluminum biphenoxide moiety. We also demonstrate the iridium-catalyzed C3-selective C-H borylation of pyridine with a 1,10-phenanthroline (Phen) ligand bearing an alkylborane moiety. It is proposed that the Lewis acid-base interaction between the
    我们在此报告了通过使用新设计的带有烷基苯氧化物部分的 2,2'-联吡啶 (bpy) 配体催化的酰胺的间位选择性 CH 硼酸化。我们还展示了吡啶与带有烷基硼烷部分的 1,10-咯啉 (Phen) 配体催化的 C3 选择性 CH 硼酸化。提出路易斯酸部分与基羰基或 sp2 杂化原子之间的路易斯酸碱相互作用加速反应并控制位点选择性。
  • Titanocene-Catalyzed Coupling of Aromatic Amides in the Presence of Organosilanes:  A Novel Route to Vicinal Diamines and a New Class of Amine-Substituted Oligomers
    作者:Kesamreddy Rangareddy、Kumaravel Selvakumar、John. F. Harrod
    DOI:10.1021/jo049220b
    日期:2004.10.1
    starting materials, and in high yields. In addition, the coupling of 1,4- and 1,3-bis-(N,N,N‘,N‘-tetraalkyl)arylenediamides is shown, under the same experimental conditions, to yield oligomers: R2NC(O)C6H4CH(NR2)-[CH(NR2)C6H4CH(NR2)]n-CH(NR2)C6H4C(O)-NR2 (R = methyl and ethyl; n = 0 to ca. 5). The chemical structures of these unprecedented oligomers are determined by comparison of NMR and MS spectra to
    已经针对多种具有不同取代模式的底物对标题反应进行了调查。除少数例外,该方法可从广泛获得的廉价原料中一锅法合成1,2-二胺。此外,1,4-和1,3-双-耦合器(Ñ,Ñ,Ñ “ Ñ ” -tetraalkyl)arylenediamides所示,在相同的实验条件下,得到低聚物,R 2 NC(O) C 6 H 4 CH(NR 2)-[CH(NR 2)C 6 H 4 CH(NR 2)] n -CH(NR 2)C 6 H 4 C(O)-NR 2(R =甲基和乙基;n= 0至约5)。通过将NMR和MS光谱与由类似的N,N-二烷基酰胺制备的邻位二胺的化学光谱进行比较,可以确定这些前所未有的低聚物的化学结构。限制低聚物链长的根源可能是由于内部苄基胺基团的特殊作用,因为发现底物4-Me 2 NCH 2 C 6 H 4 C(O)NMe 2与另一个4-取代的N,N研究了-二烷基酰胺。简要研究了N-甲基
  • <i>para</i> ‐Selective C−H Borylation of (Hetero)Arenes by Cooperative Iridium/Aluminum Catalysis
    作者:Lichen Yang、Kazuhiko Semba、Yoshiaki Nakao
    DOI:10.1002/anie.201701238
    日期:2017.4.18
    para‐Selective C−H borylation of benzamides and pyridines has been achieved by cooperative iridium/aluminum catalysis. A combination of iridium catalysts commonly employed for arene C−H borylation and bulky aluminum‐based Lewis acid catalysts provides an unprecedented strategy for controlling the regioselectivity of C−H borylation to give variously substituted (hetero)arylboronates, which are versatile
    酰胺吡啶的对位C-H化已通过/协同催化实现。芳烃CH化中常用的催化剂和庞大的路易斯酸催化剂的结合提供了一种空前的策略,可控制CH化的区域选择性,从而得到各种取代的(杂)芳基硼酸酯,它们是复杂的多用途合成中间体多取代的芳族化合物。
  • Pyrrolo(oxo)isoquinolines as 5HT ligands
    申请人:Fevig M. John
    公开号:US20060014777A1
    公开(公告)日:2006-01-19
    The present application describes compounds according to Formula I, pharmaceutical compositions, comprising at least one compound according to Formula I and optionally at least one additional therapeutic agent and methods of treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impared glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using compounds according to Formula I or pharmaceutically acceptable salt forms thereof, wherein A, B, D, E, m, n, R 3 , R 7 , R 8 , R 9 , R 10 , R 11 and X are described herein.
    本申请描述了根据式I的化合物,包括至少一种根据式I的化合物和可选地至少一种额外的治疗剂的药物组合物,以及治疗与调节5-羟色胺受体相关的各种疾病、症状和紊乱的方法,例如:代谢性疾病,包括但不限于肥胖症、糖尿病、糖尿病并发症、动脉粥样硬化、糖耐量受损和血脂异常;中枢神经系统疾病,包括但不限于焦虑、抑郁症、强迫症、恐慌症、精神病、精神分裂症、睡眠障碍、性功能障碍和社交恐惧症;头痛;偏头痛;以及使用根据式I的化合物或其药用盐形式治疗胃肠道紊乱,其中A、B、D、E、m、n、R3、R7、R8、R9、R10、R11和X在此处描述。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫